AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is currently conducting a Phase III clinical study titled ‘A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia.’ The study aims to evaluate the efficacy and safety of the drug AZD0780 in reducing LDL-C levels in adults with HeFH, a condition characterized by high cholesterol levels.
The intervention being tested is AZD0780, a small molecule drug designed to lower LDL-C levels in the blood. It is administered orally once daily and compared against a placebo to assess its effectiveness and safety.
This study is interventional, with a randomized, parallel-group design. It is double-blind, meaning neither participants nor investigators know who receives the drug or placebo. The primary purpose of the study is treatment-focused, aiming to provide a new option for managing high cholesterol.
The study began on June 10, 2025, and the latest update was submitted on July 22, 2025. The primary completion and estimated completion dates are yet to be announced, indicating the study is still in the recruitment phase.
For investors, this study could impact AstraZeneca’s stock performance positively if AZD0780 proves effective, as it would expand their cardiovascular treatment portfolio. However, competition in the cholesterol-lowering drug market is fierce, with several established players.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.